Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 95Breast Neoplasms, Male 6Advanced Breast Cancer 4Triple Negative Breast Neoplasms 2Neoplasms 2Neoplasm Metastasis 2Infertility 2Sexual Dysfunctions, Psychological 1Primary Ovarian Insufficiency 1Patient Compliance 1Osteitis Deformans 1Inflammatory Breast Neoplasms 1Hyperlipidemias 1Hormone-sensitive Metastatic Breast Cancer 1Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer 1Hereditary Sensory and Autonomic Neuropathies 1HER2-positive Breast Cancer 1HER2 Negative Breast Cancer 1Breast Diseases 1Breast Cancer Invasive 1Anatomic Stage I Breast Cancer AJCC v8 1Advanced Metastatic Breast Cancer 1

Interventions

Letrozole 1Goserelin 1Erlotinib Hydrochloride 13-(8-amino-1-(2-phenylquinolin-7-yl)imidazo(1,5-a)pyrazin-3-yl)-1-methylcyclobutanol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hormone-sensitive Metastatic Breast Cancer × Goserelin × Breast × Clear all
NCT01205685 2012-09-11

Endocrine Therapy + OSI-906 With or Without Erlotinib for Hormone-Sensitive Metastatic Breast Cancer

Vanderbilt-Ingram Cancer Center

Phase 2 Terminated
11 enrolled 9 charts
Breast

Hormone-sensitive Metastatic Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡